Technetium ⁹⁹ᵐTc medronic acid

Pregnancy category C.

Animal reproduction and teratogenicity studies have not been conducted with technetium Tc 99m medronic acid. It is also not known whether technetium Tc 99m medronic acid can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. There have been no studies in pregnant women. Technetium Tc 99m should be given to a pregnant woman only if clearly needed.

Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.

Technetium Tc 99m medronic acid is excreted in human milk during lactation. Therefore, formula feedings should be substituted for breast feedings.

No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or whether technetium Tc 99m medronic acid affects fertility in males or females.

Several cases of allergic dermatological reactions have been reported in association with the use of technetium Tc 99m medronic acid.

Several reactions have also been reported in association with other radiopharmaceuticals of the diphosphonate class, particularly technetium Tc 99m medronic acid. These are usually hypersensitivity reactions characterized by itching, various skin rashes, hypotension, chills, nausea, fever, and vomiting. One death secondary to cardiac arrhythmia following the administration of technetium Tc 99m medronic acid has been reported. In addition, one case of cardiac arrest in a patient also undergoing pulmonary function testing one and one-half hours after the performance of a bone scan using technetium Tc 99m medronic acid has been reported.